Sponsors & Workshops
Cellexus research, develop and manufacture the CellMaker range of revolutionary single-use, airlift bioreactor systems and related technology.
The most innovative airlift technology on the market, the CellMaker system offers a reduced investment alternative to existing technologies with a combined low footprint and excellent performance. The CellMaker bioreactors are available in 8L and 50L and the option of fitted sensors for pH and dissolved oxygen to enhance process control, maximise yields and reduce time to market. The CellMaker range is designed to be versatile and has been proven in a wide range of cell lines (E Coli, Pichia, Bacteriophage, Yeast, Algae) for fermentation applications used in the life sciences and biopharmaceutical industries. We enable our customers to accelerate their processes and increase their yields when compared to standard methods.
Workshop and demo
Cellexus are delighted to present the CellMaker Low Flow bioreactor system in this workshop. We will demonstrate the system on-site and detail some of the exciting results already being achieved by our clients.
The CellMaker Low Flow single-use, airlift bioreactor system is specially designed to improve mammalian cell culture. Our innovative airlift technology allows for gentle yet efficient mixing, while our single-use bioreactor bags eliminate cross-contamination. Our system is self-contained, with no mechanical moving parts, offering extremely low shear stress.
Cellexus also offer a Regular, Dual Regular and Plus CellMaker systems, designed for a range of cell culture and fermentation requirements, in working volumes from 3L to 50L.
Find out more about Cellexus and the CellMaker on our website: Cellexus
ChemoMetec A/S is a Danish founded company specializing in the development and manufacturing of automated Cell Counters, Advanced Cell Analysers and Image Cytometers. We help streamline research, process development, manufacturing and quality control processes. Through a unique technology platform, our instruments ensure high-quality analysis of results and data consistency between users/instruments. The instruments are known for their robustness and high precision, with advanced analysis capabilities and a user-friendly interface.
Our technology is rapidly becoming the gold standard for cell count and viability in the fields of Cell and Gene Therapy. This because our cell counters deliver the highest level of precision and advanced analysis capabilities, as well as being 21CFR part 11-ready. With the Via-Cassette™, we eliminate user errors from sample handling, counting and analysis, and individual volume-calibration ensures the most accurate calculation of cell concentration. These features eliminate variation between your analyses and ensure reliable monitoring of cell cultures across users and sites.
Workshop and demo
During the workshop we will demo our latest automated cell counter, the NucleoCounter®NC-202™. We will explain how we have minimised user and instrument variation and how to do a quick and reliable cell count. This will be followed by a discussion on how to validate any cell counting method, irrespective of the type of the cell type or the method used (e.g. manual counting or any type of automated cell counter).
More information on our Automated Cell Counters & Viability Analysers can be found below.
Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. Used by scientists and clinicians around the world, our technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, and cell culture. Our 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer. Today, Miltenyi Biotec has about 3,000 employees in 28 countries – all dedicated to helping researchers and clinicians make a greater impact on science and health.
Automated manufacturing of adherent cells is a technical challenge. Adherent cells require large cultureware surfaces and periodic passaging procedures to realize cell manufacturing at desired qualities and scales. In addition, some cell types may require pre-coated cultureware to which they can attach to.
Workshop and demo
During the workshop we will demo our latest application: The CliniMACS Prodigy Adherent Cell Culture System, a cell manufacturing process on the CliniMACS Prodigy Platform. The CliniMACS Prodigy Adherent Cell Culture System allows for GMP-compliant and scalable manufacturing of different adherent cell types, such as PSCs, their derivatives, and MSCs.
Sexton Biotechnologies is a company focused on the development and sales of bioproduction tools for cell and gene therapy. Founded in 2019, located in Indianapolis, IN. Sexton develops purpose-built CGT tools and media to enable flexible automation and scaling of cell manufacturing processes to increase the probability of positive clinical outcomes and reduce time-to-market, failure points, and labor costs. Sexton’s portfolio includes their Processing and Handling platform technologies, incorporating the Signata CT-5 flexible automation device and their CellSeal platform of cryo-storage tools and fill/finish systems, as well as their Cell Performance offering encompassing high quality human platelet lysate growth supplements.
During the workshop we will consider the effect of ancillary materials on cell manufacturing processes, suggesting potential strategies to mitigate variability and ensure reproducible, reliable and robust ATMP production. In addition, we will address challenges of fluid transfer within cell and gene therapy processes, presenting a potential solution in the Signata CT-5, which allows for cost effective, early implementation of semi-automated processes with control and electronic record, whilst maintaining a high degree of flexibility that supports users in research, development or commercial stage manufacture.
VivaBioCell develops, manufactures and commercializes automated solutions for the manufacturing of advanced therapy medicinal products, for both research and clinical applications. VivaBioCell is part of NantWorks LLC group (Culver City, California) which supports an ecosystem of companies focused on the development and commercialization of innovative therapies, operating at the intersection of research, infrastructure and market. VivaBioCell’s mission is to provide smart and cost-effective solutions that allow for the improvement and standardization of advanced therapies manufacturing. VivaBioCell technology, together with the strong commitment in supporting the customers during all phases of set-up and validation, allow for a safe seamless conversion of a manual protocol into a high-standardized scalable process, drawing the attention on risk reduction and cost containment, while maintaining regulatory and quality requirements. Indeed, VivaBioCell truly wants to inspire the application and diffusion of sustainable advanced therapies, with the long-term vision of bridging regenerative medicine into the mainstream worldwide clinical practice.
VivaBioCell will present the NANT 001 and NANT XL automated systems for cell expansion, functionally closed bioreactors designed to overcome the challenges of GMP-compliant manufacturing of ATMPs. These systems, able to expand both cells in adhesion and suspension, are currently being used for the manufacturing of cell-therapy products in the context of clinical trials both in Europe and U.S.A.
With decades of expertise in cellular technologies and a reputation for outstanding support and collaboration, Terumo Blood and Cell Technologies is proud to be a leader in cell collection, separation, and expansion technologies used in the production of cellular therapies. Our scientists, engineers, and cell processing specialists are united in their commitment to helping customers address challenges, find solutions, and refine processes within the development process from start to finish serving the entire spectrum: hospitals to research centers to manufacturers in cGMP environments.
Workshop & Demo
Terumo Blood and Cell Technologies is delighted to introduce the FINIA® Fill and Finish System in this workshop. We will demonstrate the system on-site and detail some key features of this automated fill and finish device.
Finia is an automated system that formulates and aliquots fluids, including cell suspensions, to prepare for cryopreservation. It consists of a device, a handheld barcode scanner, a monitor with a touch screen and functionally closed single-use disposable tubing sets.
• You reduce the risks associated with a manual process.
• You bring precision to your fill and finish step.
• You bring consistency to your production with automated control over key variables.
• You facilitate the GMP compliance of your process.
Find out more about FINIA® Fill and Finish on our website: https://www.terumobct.com/finia
Fee & Cancellation Policy
Rate includes 2.5 days conference attendance with workshop on Day 2, coffees, lunches, a drinks reception and 2 dinners.
Early Bird Registration, before April 30th, 2021
€1,250 per attendee 2 or more from one company €1,000 per attendee
General Registration, after May 01st, 2021
€1,500 per attendee
2 or more from one company €1,250 per attendee
Academic rate available upon request.
Cancellation possible until September 30th subject to a €100.00 cancellation fee.
Accommodation is available at the Glenlo Abbey Hotel, and can be booked directly via the hotel or via e-mail at firstname.lastname@example.org using promo-code ‘HiTechHealth’. Special rate of €160 B&B single or €170 for Twin or Double.
In addition, rooms are also available at the Harbour Hotel (www.harbour.ie) located in Galway City. Bookings can be made directly via the hotel or via e-mail at email@example.com using promo-code ‘HiTechHealth’. Special rate of €129 B&B single or €139 for Twin or Double. Transfer will be organised for attendees staying in this hotel to the venue each morning of the meeting.
HiTech Health awarded with €7m government funding for 'disruptive' project HiTech Health and our partners, Relevium Medical and Professor Garry Duffy’s Laboratory at NUI Galway are honoured to receive €7 million from the Disruptive Technologies Innovation Fund...
HiTech Health and blood cancer charity Anthony Nolan have entered into an agreement to facilitate the development of novel cell and gene therapies. Anthony Nolan Cell & Gene Therapy Services will support HiTech Health’s supply chain through the provision of a...
HiTech Health, SextonBio and MedInstitute announce collaboration to develop and publish workflows for integrating unit operations in cell therapy manufacturing using flexible automation systems. Sexton Biotechnologies, in partnership with HiTech Health and Med...
Stay Up To Date
Connect with us to receive the latest HiTech Health and industry updates.